Holdings A/S Novo Sells 2,725,283 Shares of KalVista Pharmaceuticals, Inc. (KALV) Stock
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Holdings A/S Novo sold 2,725,283 shares of the company’s stock in a transaction dated Thursday, October 12th. The stock was sold at an average price of $9.64, for a total transaction of $26,271,728.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Holdings A/S Novo also recently made the following trade(s):
- On Thursday, September 14th, Holdings A/S Novo sold 10,000 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $8.05, for a total transaction of $80,500.00.
- On Wednesday, September 13th, Holdings A/S Novo sold 25,900 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $8.02, for a total transaction of $207,718.00.
- On Friday, September 15th, Holdings A/S Novo sold 176,647 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $7.21, for a total transaction of $1,273,624.87.
Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) traded down 9.40% on Thursday, hitting $9.06. 2,615,937 shares of the stock traded hands. The stock’s 50 day moving average price is $7.54 and its 200 day moving average price is $7.54. KalVista Pharmaceuticals, Inc. has a 52-week low of $5.48 and a 52-week high of $15.80. The stock’s market cap is $88.00 million.
An institutional investor recently bought a new position in KalVista Pharmaceuticals stock. Eventide Asset Management LLC acquired a new position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 98,100 shares of the specialty pharmaceutical company’s stock, valued at approximately $766,000. Eventide Asset Management LLC owned about 1.01% of KalVista Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 75.66% of the company’s stock.
KALV has been the topic of a number of recent research reports. ValuEngine upgraded shares of KalVista Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 2nd. BTIG Research began coverage on shares of KalVista Pharmaceuticals in a research note on Thursday, August 31st. They issued a “buy” rating and a $18.00 target price on the stock.
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, formerly Carbylan Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME).
Receive News & Ratings for KalVista Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.